drugset
drugset / Trial / NCT00089362

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00089362 ↗

Phase 1 Completed 30 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as alvespimycin hydrochloride, work in different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
2004-07
Primary completion
2008-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject alvespimycin Small molecule — Intravenous

Indications

adenoid cystic carcinoma cancer of unknown primary site esthesioneuroblastoma female breast carcinoma gastric carcinoma hypopharynx squamous cell carcinoma intraoral basal cell carcinoma inverted papilloma larynx verrucous carcinoma lymphoepithelial-like carcinoma male breast carcinoma malignant colon neoplasm melanoma metastatic squamous cell carcinoma nasal cavity and paranasal sinus lethal midline granuloma nasal cavity and paranasal sinus squamous cell carcinoma nasopharyngeal squamous cell carcinoma oral cavity mucoepidermoid carcinoma oropharynx squamous cell carcinoma ovarian carcinoma prostate carcinoma renal cell carcinoma salivary gland cancer verrucous carcinoma of oral cavity